Atea Pharmaceuticals, Inc. (AVIR) stock
AVIRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.96−0.16 (-3.88%)
Close on Nov 17, 2026Market cap $317.61MP/E –Yield –
Atea Pharmaceuticals cash
Cash and short-term investments held at the end of each period.
Atea Pharmaceuticals's cash was $219.47M at Jun 30, 2026. For fiscal 2025 it was $301.83M, down 33.6% from the year before. The highest annual figure on record is $850.12M in fiscal 2020.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $301.83M | -33.6% |
| FY2024 | Dec 31, 2024 | $454.72M | -21.3% |
| FY2023 | Dec 31, 2023 | $578.10M | -10.6% |
| FY2022 | Dec 31, 2022 | $646.71M | -15.4% |
| FY2021 | Dec 31, 2021 | $764.68M | -10.1% |
| FY2020 | Dec 31, 2020 | $850.12M | +3805.4% |
| FY2019 | Dec 31, 2019 | $21.77M | -37.1% |
| FY2018 | Dec 31, 2018 | $34.60M | +130.1% |
| FY2017 | Dec 31, 2017 | $15.04M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $219.47M | -42.2% |
| Q1 FY2026 | Mar 31, 2026 | $256.01M | -39.8% |
| Q4 FY2025 | Dec 31, 2025 | $301.83M | -33.6% |
| Q3 FY2025 | Sep 30, 2025 | $329.31M | -31.8% |
| Q2 FY2025 | Jun 30, 2025 | $379.71M | -24.4% |
| Q1 FY2025 | Mar 31, 2025 | $425.44M | -21.4% |
| Q4 FY2024 | Dec 31, 2024 | $454.72M | -21.3% |
| Q3 FY2024 | Sep 30, 2024 | $482.80M | -18.9% |
| Q2 FY2024 | Jun 30, 2024 | $502.20M | -17.4% |
| Q1 FY2024 | Mar 31, 2024 | $541.50M | -12.7% |
| Q4 FY2023 | Dec 31, 2023 | $578.10M | -10.6% |
| Q3 FY2023 | Sep 30, 2023 | $595.10M | -10.5% |
| Q2 FY2023 | Jun 30, 2023 | $608.10M | -11.2% |
| Q1 FY2023 | Mar 31, 2023 | $620.49M | -12.1% |
| Q4 FY2022 | Dec 31, 2022 | $646.71M | -15.4% |
| Q3 FY2022 | Sep 30, 2022 | $664.98M | -20.8% |
| Q2 FY2022 | Jun 30, 2022 | $684.48M | -16.2% |
| Q1 FY2022 | Mar 31, 2022 | $705.55M | -15.4% |
| Q4 FY2021 | Dec 31, 2021 | $764.68M | -10.1% |
| Q3 FY2021 | Sep 30, 2021 | $839.66M | +696.8% |
| Q2 FY2021 | Jun 30, 2021 | $816.46M | +605.1% |
| Q1 FY2021 | Mar 31, 2021 | $833.75M | +4762.4% |
| Q4 FY2020 | Dec 31, 2020 | $850.12M | +3805.4% |
| Q3 FY2020 | Sep 30, 2020 | $105.38M | +311.6% |
| Q2 FY2020 | Jun 30, 2020 | $115.79M | +234.7% |
| Q1 FY2020 | Mar 31, 2020 | $17.15M | +14.0% |
| Q4 FY2019 | Dec 31, 2019 | $21.77M | – |
| Q3 FY2019 | Sep 30, 2019 | $25.60M | – |
| Q4 FY2018 | Dec 31, 2018 | $34.60M | – |
| Q4 FY2017 | Dec 31, 2017 | $15.04M | – |
See a number that looks wrong?